Activity of a nitroxylated analog of daunorubicin, ruboxyl, in B-lymphoproliferative disorders

Patrizia Seminara, Fabrizio Franchi, Nina Konovalova, Claudio Pioli, Roberto Rossetti, Luigi Tubani, Gino Doria, Filippo Rossi Fanelli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A nitroxylated analog of daunorubicin, ruboxyl (RBX), showed low toxicity but significant lympholytic effect in preclinical evaluations. A series of studies in vitro and in animals demonstrate that RBX is a putative agent in the treatment of many neoplasms. We report the results of a study in mice in which RBX showed selective B-lymphocyte immunosuppression. On the basis of this experience, RBX was administered to 3 patients with multiple myeloma and two patients with Waldenström's disease. The results of this pilot clinical study show that this compound has good activity and low myelotoxicity and cardiotoxicity, but seems to be characterized by a threatening immunosuppressive effect. Copyright © 2001 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)77 - 82
Number of pages6
JournalActa Haematologica
Volume105
Issue number2
DOIs
Publication statusPublished - 2001
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Seminara, P., Franchi, F., Konovalova, N., Pioli, C., Rossetti, R., Tubani, L., ... Fanelli, F. R. (2001). Activity of a nitroxylated analog of daunorubicin, ruboxyl, in B-lymphoproliferative disorders. Acta Haematologica, 105(2), 77 - 82. https://doi.org/10.1159/000046538